Categories
Change Password!
Reset Password!
Exhalation delivery system with Fluticasone propionate enhances symptom relief and quality of life in chronic rhinosinusitis patients, whether they've had prior surgery or not, presenting a compelling non-surgical treatment option.
To combat the challenge of topical medications reaching sinus cavities, the Exhalation Delivery System with Fluticasone (EDS-FLU) has proven effective in improving symptoms, reducing sinus opacification, and enhancing quality of life for chronic rhinosinusitis patients, regardless of prior endoscopic sinus surgery, as per a study issued in “International Forum of Allergy and Rhinology”.
Endoscopic sinus surgery aims to facilitate better medication delivery by opening up the sinuses. The EDS-FLU method uses special biomechanics to efficiently deliver corticosteroids to both sinus cavities and drainage pathways. To test its effectiveness, two randomized trials (ReOpen1/2) compared EDS-FLU to placebo in 547 rhinosinusitis patients, dividing them into those who had not undergone surgery and those who had.
The endpoints ascertained were combined symptom score (CSS), congestion score [weeks 4, 8, 12], average of percentages of opacified volume (APOV) of ethmoid/maxillary sinuses on computed tomography, and sinonasal outcome test 22 (SNOT-22) total score [week 24]. EDS-FLU remarkably improved symptoms versus placebo (p < 0.05) in those with moderate–severe disease (mean CSS = 5.8, APOV = 67.2%). Surgery-naive and prior ESS groups illustrated improvements in CSS, congestion, SNOT-22, and APOV, with no vital differences between surgery subgroups (Table 1).
To sum up, there was no marked difference in effectiveness between the surgery-naive and prior-surgery groups, suggesting that EDS-FLU may be advantageous across different patient populations.
International Forum of Allergy and Rhinology
EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials
Sarah K. Wise et al.
Comments (0)